Cargando…
The biosimilar pathway in the USA: An analysis of the innovator company and biosimilar company perspectives and beyond
In order to improve access to costly biological treatments, a biosimilar pathway in the United States of America (USA) was enacted under the Biologics Price Competition and Innovation Act (BPCI Act) of 2009. The aim of the present study was to investigate how the health policy, the establishment of...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taiwan Food and Drug Administration
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307033/ https://www.ncbi.nlm.nih.gov/pubmed/31324283 http://dx.doi.org/10.1016/j.jfda.2019.03.003 |